Century Net Tangible Assets from 2010 to 2026
| IPSC Stock | USD 1.84 0.09 4.66% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 348.1 M | Current Value 365.6 M | Quarterly Volatility 212.8 M |
Check Century Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Century Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 32.4 M or Total Revenue of 5.6 M, as well as many indicators such as Price To Sales Ratio of 13.17, Dividend Yield of 0.0 or PTB Ratio of 0.47. Century financial statements analysis is a perfect complement when working with Century Therapeutics Valuation or Volatility modules.
Century | Net Tangible Assets | Build AI portfolio with Century Stock |
Analyzing Century Therapeutics's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Century Therapeutics's current valuation and future prospects.
Latest Century Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Century Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Century Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Century Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Century Net Tangible Assets Regression Statistics
| Arithmetic Mean | 58,420,873 | |
| Coefficient Of Variation | 364.24 | |
| Mean Deviation | 196,191,953 | |
| Median | (91,859,000) | |
| Standard Deviation | 212,790,617 | |
| Sample Variance | 45279.8T | |
| Range | 502.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 15843.1T | |
| R-Squared | 0.67 | |
| Significance | 0.000056 | |
| Slope | 34,542,929 | |
| Total Sum of Squares | 724477.5T |
Century Net Tangible Assets History
About Century Therapeutics Financial Statements
Century Therapeutics stakeholders use historical fundamental indicators, such as Century Therapeutics' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Century Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Century Therapeutics' assets and liabilities are reflected in the revenues and expenses on Century Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Century Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 348.1 M | 365.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out the analysis of Century Therapeutics Correlation against competitors. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Century diversify its offerings? Factors like these will boost the valuation of Century Therapeutics. Market participants price Century higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Century Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |
Investors evaluate Century Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Century Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Century Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Century Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.